Introduction
Infection with high risk human papillomavirus (hrHPV) can cause cervical cancer [1] [2] [3] [4] , as well as anal 5, 6 , penile 7 and head-and-neck cancer 8, 9 . Men who have sex with men (MSM) are at increased risk of HPV associated anal cancer and its precursors 10 . Incidence of anal cancer ranges from 5 per 100,000 per year among HIV-negative MSM, rising to 78 per 100,000 per year among HIV-positive MSM in the combination antiretroviral therapy (cART)-era [10] [11] [12] .
Precursor lesions of anal cancer 12, 13 are histopathologically graded as anal intraepithelial neoplasia (AIN) 1, 2, and 3 and categorized as low-grade squamous intraepithelial lesions (LSIL; AIN1) or high-grade squamous intraepithelial lesions (HSIL; AIN2/3). The gold standard for anal HSIL screening is high-resolution anoscopy (HRA) with biopsy of suspicious lesions [14] [15] [16] . HRA is time-consuming, technically challenging and cumbersome for the patient. Selecting patients at risk of anal HSIL for HRA could be beneficial from a patient and health-care costs perspective. Yet, current alternative screening methods either lack sensitivity and specificity 10, [17] [18] [19] . Evaluation of demographic-, behavioral-and HIV-related factors for triage of HIV-positive MSM at higher risk of anal HSIL showed no uniform risk factors 12, 15, [20] [21] [22] [23] . Biomarkers, such as naturally acquired HPV antibodies, anal HPV persistence and anal HPV viral load, might also be used as predictors of anal HSIL. Serum antibodies against proteins of HPV are of interest as potential predictors of anal HSIL, as they were shown to be strong predictors of anal 24 and oropharyngeal cancer 25, 26 . Therefore, the aim of this study was to assess the predictive power of anal HPV persistence, anal hrHPV viral load and seropositivity for different HPV proteins (L1,E6,E7,E1,E2) for the presence of anal HSIL among HIV-positive MSM.
Methods
Study participants Study design and sample collection of the HIV & HPV in MSM (H2M) study have been previously described 19 . In brief, HIV-negative and HIV-positive MSM aged ≥18 years were recruited for a prospective cohort study in 2010-2011 at three sites in Amsterdam, the Netherlands 19 . Participants were followed up approximately every 6 months, for a maximum period of 24 months per person. Within the H2M2 study, analyses were done in two different ways: (1) Studying predictors of anal HSIL on patient-level, in which the anal HSIL diagnosis was based on histology done by the pathology department of the clinic where the HRA was done; (2) Studying predictors of anal HSIL with known causative HPV type, in which the HPV type-specific HSIL diagnosis was based on histology and on results of whole tissue section analysis and, if indicated, laser capture microdissection of the anal biopsies. * No left-over tissue or HSIL not confirmed in re-assessment of available left-over tissue of the biopsy.
HRA was offered to HIV-positive participants in three clinics in Amsterdam during the study period: the Academic Medical Center (AMC), Onze Lieve Vrouwe Gasthuis (OLVG), and DC Klinieken. Only HIV-positive H2M participants who underwent a first HRA after their last H2M visit in one of these three clinics before December 2015 were included in this study (Figure 1 ). The Medical Ethics Committee of the AMC approved this study [MEC 07/182] and all participants provided written informed consent prior to enrolment.
Data collection
At each H2M visit, participants completed a self-administered questionnaire. Venous blood, and anal self-swabs were collected [regular flocked swab with 1 ml Universal Transport Medium (UTM); Copan, Brescia, Italy] 19 . HIV-related data were obtained from the Dutch HIV Monitoring Foundation 27 . Clinical information related to the HRA was obtained from the infectious diseases physician or dermatologist.
Human papillomavirus DNA detection and genotyping DNA detection and HPV genotyping of the anal samples has been previously described 19 . Briefly, DNA extraction was performed using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Mannheim, Germany). Broad-spectrum HPV DNA amplification was performed using the highly sensitive SPF10-PCR DEIA/LiPA25 system (version 1) 28 . Persistent HPV infection was defined as at least three positive anal samples of the same HPV-type, with a maximum of one negative anal sample in between.
HPV viral load determination
Type-specific hrHPV anal viral load was determined if a participant was positive for HPV16, 18, 31, 33, 45, 52 ,58 at the last H2M visit. Viral load was determined using a previously described type specific L1-targeting quantitative qPCR protocol optimized to approach SPF10-LiPA25 sensitivity levels 29, 30 . HPV viral loads were standardized for the amount of human cells present in each sample via a β-actin qPCR 30 . qPCRs were performed in 20µl final volume using LightCycler TaqMan Master on the Roche LightCycler 480 platform (Roche Diagnostics, Almere, the Netherlands). The typespecific median anal HPV viral load was determined, after which categorical variables by hrHPV-type were made, grouping participants in three groups: no HPV infection, positive with HPV viral load ≤median, and positive with HPV viral load >median HPV viral load.
Serology
All serum samples were stored at -80°C until analysis. HPV antibody detection against L1, E6, E7 for HPV-types 6, 11, 16, 18, 31, 33, 45, 52, 58 , and against E1 and E2 for HPV-types 16 and 18 was conducted simultaneously using a glutathione Stransferase multiplex assay 31 . Antibody specific seropositivity for all HPV antigens was calculated based on standardized serology cutoff values ( Supplementary table 1 ).
HRA procedure
The HRA procedure has been described previously 20, 32, 33 . Briefly, HRA consisted of a digital rectal examination followed by intra-and perianal inspection with a highresolution colposcope after repeatedly applying acetic acid (3-5% solution) and staining with Lugol's iodine when indicated. Areas suspicious for squamous intraepithelial lesions (SIL) were biopsied.
Histopathology
Biopsied lesions were graded by specialized pathologists. In two out of three clinics, pathologists used p16 staining for AIN2 grading of biopsies, as recommended by the College of American Pathologists 16 . The highest grade biopsy defined the overall diagnosis. Available left-over tissue of biopsies of participants with anal HSIL was reevaluated at DDL Diagnostic Laboratory, Rijswijk, the Netherlands. Reassessment entailed morphological examination of a newly cut Haematoxylin and Eosin (H/E) stained slide with supportive use of p16, by two specialized pathologists. HPV-types in the lesion were determined by genotyping using the SPF10-PCR DEIA/LiPA25 system (version 1) on the whole tissue section (WTS) and, if WTS analysis yielded more than one HPV-type, on specific lesions after laser capture micro-dissection 28, 33, 34 .The single HPV-type found in a lesion was called the causative HPV-type.
Statistical analyses
Differences in characteristics between men without anal HSIL (no anal HSIL/AIN1) and with anal HSIL (AIN2/AIN3) were assessed by using Chi-squared or Fisher's exact tests for categorical variables and Wilcoxon rank-sum tests for continuous variables.
Prediction of anal HSIL Analyses on prediction of anal HSIL were conducted on two levels: patient-level and causative HPV-type-level ( Figure 1 ).
For the patient-level analyses a dataset was created of one record per participant with the outcome anal HSIL (regardless of causative type) vs. no anal HSIL. Univariable and multivariable logistic regression was conducted to study the predictive power of each biomarker for anal HSIL diagnosis. Variables associated at P<0.2 in the univariable model were assessed in multivariable analysis, using a backward selection method.
For the causative HPV-type-level analyses a dataset was created of one record per HPV-type per patient. Each record included a value for HSIL: 1 if the patient had HSIL caused by that particular type and 0 if the patient did not have HSIL caused by that particular HPV-type. Of some lesions the HSIL diagnosis could not be confirmed ( Figure  1 ), because no left-over tissue was available, or no HSIL was detected in the left-over material of the lesion. As these HSIL could not be assigned to an HPV-type, these men were excluded from the analyses. Univariable and multivariable logistic regression analyses using generalized estimating equations (GEE) was done to determine the association of type-specific biomarkers with type-specific anal HSIL diagnosis. GEE accounted for multiple observations (different HPV-types) within the same participant. The main dataset consisted of data on HPV-types 6, 11, 16, 18, 31, 33, 45, 52, 58. As there were 193 men in this study, this dataset contained 1737 records. Biomarkers associated in univariable regression at P<0.2 were included in multivariable logistic regression using GEE. A backward selection procedure was done to obtain a parsimonious model. 20 and time between last H2M visit and HRA were included as potential determinants. If determinants were found in any of the multivariable analyses, accuracy of the determinant as a predictor was assessed using a receiver operator curve (ROC) to estimate the area under the ROC curve (AUC).
In both types of analyses age, number of years living with viral suppression
Sensitivity analyses on both patient-level and causative HPV-type-level were done by using AIN2 vs. no anal HSIL, and AIN3 vs. no anal HSIL as outcome. Further sensitivity analyses on HPV-type-level were done on datasets with different combinations of HPV-types: (1) HPV-types 16 and 18; (2) HPV-types 16, 18, 31, 33, 45, 52, 58; (3) HPV-types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 ; (4) HPV-types 6 and 11. Also two other definitions of persistence were tested, having: (1) at least four positive anal HPV samples; (2) at least two consecutive positive anal samples. Also two definitions of single positive visits were assessed: (1) at least one positive visit; (2) positive at the last H2M visit. Finally, sensitivity analyses were done on hrHPV viral load to assess the association between anal HSIL and hrHPV viral load as a continuous variable. For this, standardized Z-scores of the log-transformed type-specific anal hrHPV viral load were used to account for natural differences in hrHPV viral load between different hrHPV-types. The association of anal hrHPV viral load with anal HSIL was assessed using restricted cubic splines, with knots at the 20th, 40th, 60th, and 80th percentiles.
Results
In total, 193 HIV-positive MSM were included in this analysis, of whom 50 (26%) had anal HSIL based on the histopathological diagnosis of the clinic's own pathology department ( Figure 1 ). The mean age was 50 years (standard deviation (SD) 10). Nearly all MSM were on cART (n=188; 97%), the mean CD4 T-cell count was 681 cells/µl (SD 250) and the mean nadir CD4 T-cell count was 245 cells/µl (SD 134). Educational level was the only characteristic in which a borderline significant difference was found between participants with and without anal HSIL (p=0.05) ( Table 1) .
Anal HPV persistence of the two low-risk (6, 11) and seven hrHPV-types (16, 18, 31, 33, 45, 52, 58) was common, with persistence for HPV16 in 19% of study participants. The highest proportion persistence was found for HPV6 (22%) ( Table 2 &  Supplementary table 2 ). The highest hrHPV viral load was found for HPV16, with a median 57.4 DNA copies/human cell (interquartile range (IQR): 8.7-586.2) ( Table 2) . L1 seropositivity at last H2M visit was common, with 37 participants (19%) being HPV16 seropositive. E1, E2, E6 and E7 seropositivity was rare. HPV16 seropositivity was 3% for E1, 1% for E2, 3% for E6, and 1% for E7 ( Table 2) .
Patient-level results
In univariable logistic regression analyses on patient-level, age, years living with viral suppression and time between last H2M visit and HRA were not significantly associated with anal HSIL (Table 3 ). Of the assessed biomarkers, only HPV16 and HPV35 persistence were significantly associated with anal HSIL (odds ratio (OR) 2.46, Table 2 . -: not measured; * 3 positive visits with max. 1 negative visit in between; ** Measured at last H2M visit: for most of the men this was visit #5, but for some this was visit #4, or #3, or #2; *** as established by whole tissue section genotyping and laser capture microdissection if more than one HPV type was found in whole tissue section.
95% confidence interval (CI) 1.12-5.39, and OR 3.28, 95%CI 1.16-9.32, respectively). Neither anal hrHPV viral load nor any of the serological markers were associated with anal HSIL. Univariable associations were largely the same using AIN2 or AIN3 as outcomes, instead of HSIL (Table 3 ). In multivariable logistic regression, anal HPV16 and HPV35 persistence remained significantly associated with anal HSIL (adjusted OR 2.41, 95%CI 1.09-5.35, and adjusted OR 3.19, 95%CI 1.10-9.23, respectively). In multivariable logistic regression with AIN2 as outcome, anal HPV16 persistence and HPV18 L1 seropositivity were significantly associated with the outcome. In multivariable logistic regression with AIN3 as outcome, HPV33 and HPV35 persistence were significantly associated with the outcome (Table 4 ). Anal HPV16 persistence was a very weak predictor of anal HSIL, with an area under the ROC-curve of 0.58. Sensitivity analyses with different definitions of persistence gave similar results (data not shown).
HPV-type-level results
In the 50 patients with HSIL, HSILs could be attributed to a causative HPV-type in 26 patients, including 23 AIN2 lesions and 12 AIN3 lesions. In the other 24 patients HSIL was not diagnosed in the left-over material at the second histopathological examination. Characteristics of this study population are provided in Supplementary  table 3 .
Including HPV-types 6, 11, 16, 18, 31, 33, 45, 52, 58, in univariable logistic regression using GEE, age, years living with viral suppression and time between last H2M visit and HRA were not significantly associated with anal HSIL with known causative HPV-type (Supplementary table 4 ). Neither anal hrHPV viral load nor any of the serological markers were associated with anal HSIL by the concordant HPV-type. Type-specific anal HPV persistence was the only biomarker significantly associated with anal HSIL caused by the concordant HPV-type (OR 14.68, 95%CI 6.16-35.02, P<0.001) (Figure 2 ). The area under the ROC curve for the prediction of type-specific anal HSIL by type-specific persistence was 0.60 (data not shown).
In the datasets including different combinations of HPV-types (including HPV-types 16 and 18; HPV-types 16, 18, 31, 33, 45, 52, 58; HPV-types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) , anal HPV persistence remained the only significantly associated biomarker of anal HSIL caused by the concordant HPV-type ( Figure 2) . The associations between anal HPV persistence, anal hrHPV viral load and seropositivity for L1, E6, E7, E1, E2 remained largely the same when AIN2 or AIN3 were used as outcomes (Supplementary figure 1) . However, type-specific anal HPV persistence was no longer significantly associated when AIN3 was used as outcome.
As the persistence definition is arbitrary, we assessed the effect of different definitions of persistence on the association with anal HSIL: at least 4 positive visits, 3 positive visits with a maximum of one negative visit in between (main definition used), 2 consecutive positive visits, at least once positive, positive at last H2M visit. We assessed all definitions in the four datasets including different combinations of HPVtypes, for all three outcome measures (HSIL vs no HSIL, AIN2 vs no HSIL, AIN3 vs no HSIL). The association between anal HPV persistence and anal HSIL caused by the concordant HPV-type remained strong for all definitions of persistence, irrespective of the included HPV-types ( Figure 3 ). The strength of the association between anal HPV persistence and type-concordant anal HSIL diagnosis could not be assessed when only HPV6 and 11 were included, due to limited power. However, all participants with anal HSIL caused by HPV6 or 11 had a persistent anal HPV infection of that type. All associations with persistence remained largely the same when AIN2 or AIN3 were used as outcome (data not shown). Assessment of anal hrHPV viral load as a continuous variable showed no significant association (P=0.3) with anal HSIL caused by the concordant HPV-type (Supplementary figure 2 ).
Discussion
In this study we assessed associations of HPV related biomarkers and anal HSIL among HIV-positive MSM in Amsterdam, the Netherlands. Of the biomarkers anal HPV persistence, anal hrHPV viral load, and seropositivity for L1 and various E antigens, only anal HPV16 and HPV35 persistence were significantly associated on a patient level. On HPV-type level, anal HPV persistence was the only biomarker significantly associated with anal HSIL caused by the concordant HPV-type. The discriminatory power, expressed as the AUC of the ROC, of persistence as biomarker for anal HSIL was too weak to use persistence as screening tool for anal HSIL screening in HIV-positive MSM.
Persistence of anal HPV infection is considered a requirement for development of anal HSIL and eventually progression to anal cancer 15, 35, 36 . To our knowledge, the use of anal HPV persistence as a biomarker for the presence of anal HSIL has not been studied before. Abbreviations: CI -confidence interval; HIV -human immunodeficiency virus; HPV -human papillomavirus, HSIL -high-grade squamous intraepithelial lesion, LCM -laser capture microdissection, MSM -men who have sex with men, AIN -anal intraepithelial neoplasia. * Persistence is defined as: at least three anal samples positive for the same HPV type. We allowed one negative sample between two positive sample per participant as long as he had at least three positive anal samples.
** Based on small numbers (cells with zero observations) some associations were not assessable, and these biomarkers are not reported in this table. This concerns: E6 seropositivity for all HPV types other than HPV16, E7 seropositivity for all HPV type other than HPV33, E1 seropositivity for HPV16, E2 seropositivity for both HPV16 and HPV18. # 2 participants were not included in the univariable models on persistence, because they had no anal sample. Ϯ Participants who never had an undetectable viral load are included in the category <3 years undetectable viral load. § viral suppression was defined as having a viral load of <200 copies/ml in tests from 1 August 1999 onwards allowing for a onetime blip in viral load between 200 and 400 copies/ml. For samples tested prior to 1 August 1999 the cut-off of detectability of the laboratory assay that was used for that sample is the cut-off for viral suppression. 
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Abbreviations: CI -confidence interval; HIV -human immunodeficiency virus; HPV -human papillomavirus, HSIL -high-grade squamous intraepithelial lesion, MSM -men who have sex with men, AIN -anal intraepithelial neoplasia.
* Persistence is defined as: at least three anal samples positive for the same HPV type. We allowed one negative sample between two positive sample per participant as long as he had at least three positive anal samples.
# 10 participants were not included in the multivariable models, because they had <3 H2M visits resulting in no estimation for persistence according to this definition, or they had no anal sample.
The hrHPV viral load in anal swabs has previously been found to be a determinant for histologically proven anal HSIL among HIV-positive and among HIV-negative MSM 37 . In the analysis where we categorized anal hrHPV viral load, the observed association with anal HSIL merely reflected anal hrHPV infection; when we assessed hrHPV viral load as a continuous variable no significant association was found. Thus, we could not confirm the previously found association between anal hrHPV viral load and anal HSIL. This might be explained by the inclusion of anal samples obtained at the last H2M visit. In some cases this was 1.3 years prior to HRA, while Jin and colleagues 37 assessed anal hrHPV viral load of the swab taken at the same consultation as the HRA was done. The rate of spontaneous regression of anal HSIL was 19.2/100 person-years in an Australian study among 574 HIV-positive MSM 38 . Therefore, some anal HSIL lesions in our study might have regressed by the time HRA was performed.
All participants with anal HSIL caused by HPV6 or 11 had a persistent anal HPV infection of that type. Furthermore, the strength of the association between anal HPV persistence and anal HSIL was not affected by including or excluding HPV6 and 11 from analyses. HPV6 and 11 are known as low-risk HPV-types, but they have been previously found to cause anal HSIL 39 , and also anal cancer 6, 40, 41 . The progression rate to anal cancer of anal HSIL caused by low risk HPV-types is not clear.
HPV E6 seropositivity has been found to be predictive for HPV-induced oropharyngeal- 25, 26 , oropharynx-42 , and anal cancer 24 , but we could not confirm this for anal HSIL.
Strengths and limitations
This study is unique because it is the first longitudinal study able to assess the association of a range of potential virological biomarkers with histologically proven anal HSIL. Moreover, in a selection of lesions we were able to determine the causative HPV-type, thus allowing to analyze data both on patient-level and on causative HPVtype-level. A limitation of this study is the interval between sample collection for the biomarkers and establishing the histopathological HSIL endpoint via HRA. However, when correcting for time between last H2M visit and HRA, results remained largely the same. Additionally, positivity of some biomarkers, like E6 or E7 antibody positivity, was relatively rare, resulting in the inability to assess the value of these biomarkers in a Odds ratios are displayed on a logarithmic scale. For E2, E6, E7 seropositivity, no odds ratio and 95% confidence intervals are shown because these biomarkers were unassessable due to small numbers. Furthermore, not all biomarkers were measured for all HPV types. Therefore not all biomarkers could be assessed in all datasets. * Persistence is defined as: at least three anal samples positive for the same HPV type. We allowed one negative sample between two positive samples per participant as long as there were at least three positive anal samples. HPV viral load at last H2M visit was only measured for HPV16 and HPV18. Seropositivity at last H2M visit is defined as seropositive above the standard cut-off at the last H2M study visit. L1, E6 and E7 antibodies were measured for HPV types 6, 11, 16, 18, 31, 33, 45, 52 , and 58; antibodies against E1 and E2 were only measured for HPV types 16 and 18. Abbreviations: OR -odds ratio; HIV -human immunodeficiency virus; HPV -human papillomavirus, HSIL -high-grade squamous intraepithelial lesion, MSM -men who have sex with men, GEE -generalized estimating equations.
Figure 3. Number of visits with HPV positive anal sample and its association with anal HSIL with known causative HPV type; results from univariable logistic regression using GEE with different HPV types included.
Odds ratios are displayed on a logarithmic scale. In the analyses of "At least 4 positive visits" 155 men were included. In the analysis of "3 positive visits" 162 men were included; in the analysis with "2 consecutive visits" 167 men were included; and in the analyses "At least one positive visit" and "Positive at last H2M visit" 169 men were included. * At least three anal samples positive for the same HPV type. We allowed one negative sample between two positive sample per participant as long as there were at least three positive anal samples. Abbreviations: OR -odds ratio; HIV -human immunodeficiency virus; HPV -human papillomavirus, HSIL -high-grade squamous intraepithelial lesion, MSM -men who have sex with men, GEE -generalized estimating equations. limited sample size. Finally, we were not able to identify a causal HPV type for some patients with anal HSIL.
Conclusion
Anal HPV persistence is strongly associated with anal HSIL among HIV-positive MSM, compatible with the current theory on the etiogenesis of anal HSIL. Although * At least three anal samples positive for the same HPV type. We allowed one negative sample between two positive sample per participant as long as there were at least three positive anal samples. Abbreviations: OR -odds ratio; HIV -human immunodeficiency virus; HPV -human papillomavirus, HSIL -high-grade squamous intraepithelial lesion, MSM -men who have sex with men, GEE -generalized estimating equations. limited sample size. Finally, we were not able to identify a causal HPV type for some patients with anal HSIL.
Anal HPV persistence is strongly associated with anal HSIL among HIV-positive MSM, compatible with the current theory on the etiogenesis of anal HSIL. Although * Variable from the baseline visit of H2M study ** For the HPV type-level analyses a dataset was created of one record per HPV type per patient. Each record included a value for HSIL; this was 1 if the patient had an HSIL caused by that particular type and 0 if the patient did not have HSIL. Of some lesions the HSIL diagnosis could not be confirmed, therefore these records are excluded. This may be because in the left-over material of the lesion no HSIL was remaining, or because of an initial mis-diagnosis of HSIL. As these HSIL diagnoses could not be assigned to an HPV type, they were excluded from the analyses.
# Significance of differences between participants with and without anal HSIL was assessed by Chi-square tests or Fisher exact test for categorical variables and Wilcoxon rank-sum tests for continues variables. 
